Contemporary Atrial Fibrillation Management - Addressing Increased Detection, Early Rhythm Control, and Role of Antiarrhythmic Drugs
Released On
January 18, 2025
Expires On
January 18, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Acute Care, Anesthesiology, Atrial Fibrillation, Cardiology, Critical Care, Emergency Medicine, Gastroenterology, Hospitalist, Pharmacy, Primary Care, Pulmonology, Surgery
Topic(s)
Cardiovascular Disease, Heart, Heart Disease
This activity is jointly provided by P2P Syncro, and Postgraduate Institute for Medicine.
This activity is supported by an independent grant from Sanofi.
Credit Available
- Physicians — maximum of 1 AMA PRA Category 1 Credits™
- Nurses — 1 Nursing Contact Hour
- Physician Assistants — 1 CE Credit
- Pharmacists — 1 Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of cardiologists, electrophysiologists, primary care providers, and other healthcare professionals involved in the management of atrial fibrillation (e.g., providers in ER, critical care, GI endoscopy).
Program Overview
In the past, rate control beat rhythm control in the management of atrial fibrillation (AF). In recent years, the benefit of early and continued rhythm control in patients with atrial fibrillation has been demonstrated in clinical trials and real-world studies. This resulted in a guideline update. This CME will focus on the data that support early rhythm control and the role of antiarrhythmic drugs for atrial fibrillation.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Assess recent data and guideline updates that support early and continued rhythm management in AF.
- Recognize the clinical settings where rhythm control should be initiated based on evidence and new recommendations.
- Manage and treat FOP in the era of disease specific therapies.
- Develop plans on how to select antiarrhythmic drugs (AADs) and how to optimize rhythm management with AADs.
Faculty
Peter Kowey, MD
Emeritus Chief of Cardiology, Lankenau Heart Institute; William Wykoff Smith Chair, Cardiovascular Research, Lankenau Institute for Medical Research; Professor of Medicine and Clinical Pharmacology, Thomas Jefferson University. Wynnewood and Philadelphia, PA.
Emily Zeitler, MD MHS
Associate Professor of Medicine, Geisel School of Medicine at Dartmouth-Hitchcock; Associate Professor of Health Policy, The Dartmouth Institute. Lebanon, NH. Dr. Zeitler specializes in cardiac electrophysiology.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and P2P Syncro. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Education
PIM designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™sicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.
Pharmacy Continuing Education
PIM designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-25-032-H01-P)
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within within 60 days.
PA Continuing Medical Education
PIM has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 1/18/2026. PAs should only claim credit commensurate with the extent of their participation.
Disclosures of Conflicts of Interest
PIM requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PIM policies. Others involved in the planning of this activity have no relevant financial relationships.
- Dr. Peter Kowey, faculty for this educational activity, has the following relevant financial relationships:
- Consultancy/Advisory Board: Sanofi, Acesion, InCardia, Milestone, Cardurion, HUYA, Pfizer, Novartis
- Dr. Emily Zeitler faculty for this educational activity, has the following relevant financial relationships.
- Grant/Research Support: Boston Scientific, Biosense Webster, Sanofi, NIH/NIGMS.
- Consultancy/Advisory Board: Medtronic, Abbott, Boston Scientific, Biosense Webster, Sanofi, V-Wave, Edwards Lifesciences, Element.
The planners of this activity have nothing to disclose.
Instructions for Participation and Credit
Participation in this self-study activity should be completed in approximately 1.0 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from 1/18/2025 through 1/18/2026:
- Review the objectives and disclosures
- Complete activity pre-test(s)
- Study the educational content
- Visit (insert URL)
- Complete activity post-test(s)
- Complete the activity evaluation
You must respond to all evaluation questions to receive a certificate.
For Pharmacists: Upon successfully completing the post-test and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within sixty (60) days to make sure the credit has been posted.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For additional information about the accreditation of this activity, please visit https://pimed.com.